These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

668 related items for PubMed ID: 23758100

  • 1. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
    Jimenez-Yuste V, Núñez R, Romero JA, Montoro B, Espinós B.
    Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
    [Abstract] [Full Text] [Related]

  • 2. Cost and effectiveness of treatments for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors in Korea.
    You CW, Lee SY, Park SK.
    Haemophilia; 2009 Jan; 15(1):217-26. PubMed ID: 18754800
    [Abstract] [Full Text] [Related]

  • 3. Cost-Effectiveness of rFVIIa versus pd-aPCC in the Management of Mild to Moderate Bleeds in Pediatric Patients with Hemophilia A with Inhibitors in Mexico.
    Rodríguez-Zepeda MDC, González L, Bravo A, Pompa T, Silva S, Paredes R, García J, Ramos M, Wilkinson L, Lamotte M.
    Value Health Reg Issues; 2018 Dec; 17():164-173. PubMed ID: 30317158
    [Abstract] [Full Text] [Related]

  • 4. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
    Salaj P, Penka M, Smejkal P, Geierova V, Ovesná P, Brabec P, Cetkovsky P, Kubes R, Mesterton J, Lindgren P.
    Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
    [Abstract] [Full Text] [Related]

  • 5. Cost analysis of prophylaxis with activated prothrombin complex concentrate vs. on-demand therapy with activated factor VII in severe haemophilia A patients with inhibitors, in Spain.
    Villarrubia R, Oyagüez I, Álvarez-Román MT, Mingot-Castellano ME, Parra R, Casado MA.
    Haemophilia; 2015 May; 21(3):320-329. PubMed ID: 25855214
    [Abstract] [Full Text] [Related]

  • 6. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.
    Hay JW, Zhou ZY.
    Haemophilia; 2011 Sep; 17(5):e969-74. PubMed ID: 21649802
    [Abstract] [Full Text] [Related]

  • 7. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression.
    Treur MJ, McCracken F, Heeg B, Joshi AV, Botteman MF, De Charro F, Van Hout B.
    Haemophilia; 2009 Mar; 15(2):420-36. PubMed ID: 19335751
    [Abstract] [Full Text] [Related]

  • 8. A cost evaluation of treatment alternatives for mild-to-moderate bleeding episodes in patients with haemophilia and inhibitors in Brazil.
    Ozelo MC, Villaça PR, De Almeida JO, Bueno TM, De Miranda PA, Hart WM, Karamalis M.
    Haemophilia; 2007 Sep; 13(5):462-9. PubMed ID: 17880430
    [Abstract] [Full Text] [Related]

  • 9. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand.
    Mehta DA, Oladapo AO, Epstein JD, Novack AR, Neufeld EJ, Hay JW.
    J Manag Care Spec Pharm; 2016 Feb; 22(2):149-57. PubMed ID: 27015254
    [Abstract] [Full Text] [Related]

  • 10. Pharmacoeconomic analysis of recombinant factor VIIa versus APCC in the treatment of minor-to-moderate bleeds in hemophilia patients with inhibitors.
    Joshi AV, Stephens JM, Munro V, Mathew P, Botteman MF.
    Curr Med Res Opin; 2006 Jan; 22(1):23-31. PubMed ID: 16393427
    [Abstract] [Full Text] [Related]

  • 11. [Health economics of inhibitor bypassing agents in haemophilia A-activated prothrombin complex concentrate (aPCC) and recombinant activated factor VIIa (rFVIIa)].
    Szmurło D, Deryło Ł, Ryś P, Władysiuk M.
    Pol Merkur Lekarski; 2011 Mar; 30(177):202-7. PubMed ID: 21544998
    [Abstract] [Full Text] [Related]

  • 12. Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX.
    Lyseng-Williamson KA, Plosker GL.
    Pharmacoeconomics; 2007 Mar; 25(12):1007-29. PubMed ID: 18047387
    [Abstract] [Full Text] [Related]

  • 13. Experiences in the prevention of arthropathy in haemophila patients with inhibitors.
    Jimenez-Yuste V, Rodriguez-Merchan EC, Alvarez MT, Quintana M, Martin-Salces M, Hernandez-Navarro F.
    Haemophilia; 2008 Nov; 14 Suppl 6():28-35. PubMed ID: 19134031
    [Abstract] [Full Text] [Related]

  • 14. aPCC vs. rFVIIa for the treatment of bleeding in patients with acquired haemophilia - a cost-effectiveness model.
    Kim CH, Simmons SC, Bui CM, Jiang N, Pham HP.
    Vox Sang; 2019 Jan; 114(1):63-72. PubMed ID: 30499154
    [Abstract] [Full Text] [Related]

  • 15. Prophylaxis therapy with bypassing agents in patients with haemophilia A and inhibitors undergoing surgery: A cost analysis in Spain.
    Mareque M, Mingot-Castellano ME, López-Fernández MF, Álvarez-Román MT, Oyagüez I.
    Eur J Haematol; 2020 Jul; 105(1):94-100. PubMed ID: 32220097
    [Abstract] [Full Text] [Related]

  • 16. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.
    Caviglia H, Candela M, Galatro G, Neme D, Moretti N, Bianco RP.
    Haemophilia; 2011 Nov; 17(6):910-9. PubMed ID: 21342367
    [Abstract] [Full Text] [Related]

  • 17. A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors.
    Knight C, Danø AM, Kennedy-Martin T.
    Haemophilia; 2009 Mar; 15(2):405-19. PubMed ID: 19187191
    [Abstract] [Full Text] [Related]

  • 18. Single 270 microg kg(-1)-dose rFVIIa vs. standard 90 microg kg(-1)-dose rFVIIa and APCC for home treatment of joint bleeds in haemophilia patients with inhibitors: a randomized comparison.
    Young G, Shafer FE, Rojas P, Seremetis S.
    Haemophilia; 2008 Mar; 14(2):287-94. PubMed ID: 18081834
    [Abstract] [Full Text] [Related]

  • 19. An economic analysis of different treatments for bleeding in patients with acquired haemophilia.
    Kim CH, Simmons SC, Wang D, Najafzadeh P, Azad A, Pham HP.
    Vox Sang; 2020 Apr; 115(3):192-199. PubMed ID: 31879973
    [Abstract] [Full Text] [Related]

  • 20. Combined treatment with APCC (FEIBA®) and tranexamic acid in patients with haemophilia A with inhibitors and in patients with acquired haemophilia A--a two-centre experience.
    Holmström M, Tran HT, Holme PA.
    Haemophilia; 2012 Jul; 18(4):544-9. PubMed ID: 22348384
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.